Evidence map›Paper›PMID 26647381›Full record

ReviewThe international journal of neuropsychopharmacology2016

Neurobiological Insights from mGlu Receptor Allosteric Modulation.

Daniel E O'Brien, P Jeffrey Conn

Open access · goldAbstract readReview
In one paragraph

Review in The international journal of neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Species dependence of APurinergic signalling · 2023
    Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Daniel E O'BrienDepartment of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee (Drs O'Brien and Conn).
P Jeffrey ConnDepartment of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee (Drs O'Brien and Conn). jeff.conn@vanderbilt.edu.
Vanderbilt University · US

Funding

REGULATION OF SIGNALING BY MGLUR5R01MH062646 · NIMH · VANDERBILT UNIVERSITY · PI P Jeffrey Conn, COLLEEN M NISWENDER · 2001 to 2026
$10.9M
Research Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CUTTING, LAURIE E · 2015 to 2019
$7.1M
Functions of Metabotropic Glutamate Receptor SubtypesR37NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2014 to 2020
$3.5M
Postdoctoral Training in CNS Drug Discovery ResearchT32MH093366 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2011 to 2015
$1.0M
NICHD NIH HHS U54 HD083211NIMH NIH HHS R01 MH062646NIMH NIH HHS T32 MH093366NINDS NIH HHS R37 NS031373
6 · The paper itself

Abstract

Allosteric modulation of metabotropic glutamate (mGlu) receptors offers a promising pharmacological approach to normalize neural circuit dysfunction associated with various psychiatric and neurological disorders. As mGlu receptor allosteric modulators progress through discovery and clinical development, both technical advances and novel tool compounds are providing opportunities to better understand mGlu receptor pharmacology and neurobiology. Recent advances in structural biology are elucidating the structural determinants of mGlu receptor-negative allosteric modulation and supplying the means to resolve active, allosteric modulator-bound mGlu receptors. The discovery and characterization of allosteric modulators with novel pharmacological profiles is uncovering the biological significance of their intrinsic agonist activity, biased mGlu receptor modulation, and novel mGlu receptor heterodimers. The development and exploitation of optogenetic and optopharmacological tools is permitting a refined spatial and temporal understanding of both mGlu receptor functions and their allosteric modulation in intact brain circuits. Together, these lines of research promise to provide a more refined understanding of mGlu receptors and their allosteric modulation that will inform the development of mGlu receptor allosteric modulators as neurotherapeutics in the years to come.

Indexed as

Drug DesignAnimalsBinding SitesBrainDrug DiscoveryExcitatory Amino Acid AgonistsHumansOptogeneticsProtein BindingProtein ConformationProtein MultimerizationReceptors, Metabotropic GlutamateStructure-Activity RelationshipSynaptic TransmissionExcitatory Amino Acid AgonistsReceptors, Metabotropic Glutamateallosteric modulatorsbrain disordersGPCR biased signalingGPCR heterodimersmGlu receptor

Identifiers

PMID26647381
PMCPMC4886670
OpenAlexW2193315220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.